Crescendo Biologics to present preclinical data on its lead Humabody® candidate, CB307, at the Cell Engager Therapeutics Summit 2019

Crescendo Biologics to present preclinical data on its lead Humabody® candidate, CB307, at the Cell Engager Therapeutics Summit 2019 Cambridge, UK, 24 June 2019 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that it will be giving a talk and presenting a poster at the Cell Engager Therapeutics Summit in Boston, US, held from 25-27 June 2019. Crescendo’s Chief Medical Officer, Dr Pavel Pisa’s, talk entitled ‘Humabody® VH as T-cell Enhancing Therapeutics for Immuno-Oncology’ is focused on the beneficial attributes and planned clinical application of CB307. CB307 is a novel CD137-PSMA-HSA tri-specific that enables tumour selective T-cell activation, while minimising systemic toxicity. ‘Humabody® VH as T-cell Enhancing Therapeutics for Immuno-Oncology’ – talk by Dr Pavel Pisa 26 June, 12:00pm. Crescendo will also present a poster at the Summit, entitled ‘CB307: A novel T-cell costimulatory Humabody® VH therapeutic for PSMA-positive tumours’. The poster will show preclinical data obtained on Crescendo’s lead programme, CB307. The poster will illustrate the generation, functional characterisation and potential therapeutic application of CB307 in PSMA-positive solid tumours. -Ends- For more information, please contact: Crescendo Biologics Theodora Harold, CEO + 44 (0)1223 497140 [email protected] Instinctif Partners Melanie Toyne-Sewell, Dr Christelle Kerouedan, Deborah Bell + 44 (0)20 7457 2020 [email protected] Notes to Editors About Crescendo Biologics Ltd Crescendo Biologics is a T-cell enhancing company. Crescendo develops potent, truly differentiated Humabody® therapeutics with a focus on innovative, targeted T-cell approaches in oncology. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel CD137-PSMA bispecific for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment – avoiding systemic toxicity. The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications. Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas. For more information, please visit the website: www.crescendobiologics.com.

The release as fetched from its publisher. crescendobiologics.com ↗